In the present study, we describe the time trends in chemotherapy use in a large population-based cohort of ER+/Her2− breast cancer patients considered eligible for GEP use according to national guidelines, encompassing the period of time since the Dutch breast cancer guideline first suggested a role for GEP use until the period that the results of the GEP trials were available. This evidence concerns the gene ESR1 and breast cancer.